Երկիր: Կանադա
Լեզու: անգլերեն
Աղբյուրը: Health Canada
KETOCONAZOLE
KRAMER LABORATORIES, INC
D01AC08
KETOCONAZOLE
2%
SHAMPOO
KETOCONAZOLE 2%
TOPICAL
6/60/120ML
OTC
AZOLES
Active ingredient group (AIG) number: 0116793002; AHFS:
APPROVED
2007-07-04
1 PRODUCT MONOGRAPH NIZORAL® (ketoconazole 2% shampoo) Therapeutic Classification Topical Antifungal Agent Date of Revision: March 5, 2019 Kramer Laboratories, Inc. 440 Route 22 East, Suite 130 Bridgewater, NJ 08807 USA Distributed by: Aurium Pharma Inc. 7941 Jane St. # 105 Concord, Ontario L4K 4L6 Submission Control No.: 223778 2 NAME OF DRUG NIZORAL® shampoo (ketoconazole 2% shampoo) THERAPEUTIC CLASSIFICATION Topical antifungal agent ACTIONS In vitro studies suggest that the antifungal properties of NIZORAL® (ketoconazole) may be related to its ability to impair the synthesis of ergosterol, a component of fungal and yeast cell membranes. Without the availability of this essential sterol, there are morphological alterations of the fungal and yeast cell membranes manifested as abnormal membranous inclusions between the cell wall and the plasma membrane. The inhibition of ergosterol synthesis has been attributed to interference with the reactions involved in the removal of the 14- -methyl group of the precursor of ergosterol, lanosterol. Except for its specific pharmacologic effect, i.e., a sporicidal or fungicidal activity, ketoconazole when formulated in a 2% shampoo is not expected to exert any other pharmacodynamic effect when applied topically on the skin or hair. INDICATIONS NIZORAL® (ketoconazole) 2% shampoo is indicated for the topical treatment and prophylaxis of conditions in which the yeast Pityrosporum is involved, such as pityriasis capitis (dandruff). NIZORAL® shampoo is also indicated for seborrheic dermatitis. 3 CONTRAINDICATIONS NIZORAL® (ketoconazole) 2% shampoo is contraindicated in persons who have shown hypersensitivity to the active or excipient ingredients of this formulation. WARNINGS Irritation may occur when NIZORAL® (ketoconazole) 2% shampoo is used immediately after prolonged treatment with topical corticosteroids. To prevent a rebound effect after stopping a prolonged treatment with topical corticosteroids, it is recommended to continue applying a mild topical corticosteroi Կարդացեք ամբողջական փաստաթուղթը